215902 Carbonic Anhydrase IX Inhibitor III, Methazolamide - CAS 554-57-4 - Calbiochem

215902
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical FormulaCAS #
      C₅H₈N₄O₃S₂ 554-57-4

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      215902-50MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Glass bottle 50 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA cell-permeable thiadiazolylsulfonamide derivative that acts as a carbonic anhydrase (CA) inhibitor (Ki = 20 nM) with anti-glaucoma, anti-diabetic, and potential anti-neoplastic activity. May induce death in hypoxic tumor cells by inhibiting tumor-associated CAIX in maintaining an acidic tumor microenvironment, and blocking CAIX-dependent resistance to chemotherapy in these tumors. Shown to enhance insulin sensitivity and reduce HbA1c levels in diabetic rodent models in a dose-dependent manner. Shown to reduce oxygen and glucose-deprived cell death in primary cerebrocortical neurons by diminishing the release of cytochrome c and dissipating the mitochondrial membrane potential gradient.
          Catalogue Number215902
          Brand Family Calbiochem®
          SynonymsN-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide, Carbonic Anhydrase Inhibitor, Methazolamide, CAIX Inhibitor III
          References
          ReferencesMaren, T., et al. 1977. Invest Ophthalmol Vis Sci. 16, 730.
          Chegwidden, W. R. and Spencer, I. M. 1995. Inflammopharmacology. 3, 231.
          Wang, X., et al. 2009. Stroke. 40, 1877.
          Konstantopoulos, N., et al. 2012. Diabetes.
          Product Information
          CAS number554-57-4
          FormWhite powder
          Hill FormulaC₅H₈N₄O₃S₂
          ReversibleY
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Primary Targetcarbonic anhydrase
          Primary Target K<sub>i</sub>20 nM
          Purity≥99% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          215902

          References

          Reference overview
          Maren, T., et al. 1977. Invest Ophthalmol Vis Sci. 16, 730.
          Chegwidden, W. R. and Spencer, I. M. 1995. Inflammopharmacology. 3, 231.
          Wang, X., et al. 2009. Stroke. 40, 1877.
          Konstantopoulos, N., et al. 2012. Diabetes.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision30-October-2012 JSW
          SynonymsN-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide, Carbonic Anhydrase Inhibitor, Methazolamide, CAIX Inhibitor III
          DescriptionA cell-permeable thiadiazolylsulfonamide derivative that acts as a carbonic anhydrase (CA) inhibitor (Ki = 20 nM) with anti-glaucoma, anti-diabetic, and potential anti-neoplastic activity. May induce death in hypoxic tumor cells by inhibiting tumor-associated CAIX in maintaining an acidic tumor microenvironment, and blocking CAIX-dependent resistance to chemotherapy in these tumors. Shown to enhance insulin sensitivity and reduce HbA1c levels in diabetic rodent models in a dose-dependent manner. Shown to reduce oxygen and glucose-deprived cell death in primary cerebrocortical neurons by diminishing the release of cytochrome c and dissipating the mitochondrial membrane potential gradient.
          FormWhite powder
          Intert gas (Yes/No) Packaged under inert gas
          CAS number554-57-4
          Structure formulaStructure formula
          Purity≥99% by HPLC
          SolubilityDMSO (50 mg/ml)
          Storage +2°C to +8°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesMaren, T., et al. 1977. Invest Ophthalmol Vis Sci. 16, 730.
          Chegwidden, W. R. and Spencer, I. M. 1995. Inflammopharmacology. 3, 231.
          Wang, X., et al. 2009. Stroke. 40, 1877.
          Konstantopoulos, N., et al. 2012. Diabetes.